Reducing Cholesterol with β-CDP: Insights for NPC and AD
Niemann–Pick disease type C (NPC) and Alzheimer’s disease (AD) are neurodegenerative disorders characterised by cognitive dysfunction and neurological impairment. In
Tag: Alzheimer’s disease
A water-soluble β-cyclodextrin polymer reduces cholesterol accumulation and autophagy dysfunction in vitro and in Niemann-Pick type C disease model mice
A β-CDP (CycloLab) was used for the experiments. The purity of the β-CDP was >95 %. The β-CDP contained <1 % of
Cyclodextrins as Active Therapeutic Agents: Beyond Their Role as Excipients
Cyclodextrins (CDs) have traditionally been recognized as excipients that enhance solubility and stability of drugs. However, growing evidence shows that
CD treatment against cellular senescence
Cellular senescence, a hallmark of aging, has been implicated in Alzheimer’s disease (AD) pathogenesis. Cholesterol accumulation is known to drive
Multi Targeted Therapy for Alzheimer’s Disease by Guanidinium-Modified Calixarene and Cyclodextrin Co-Assembly Loaded with Insulin
Amyloid-β (Aβ) is considered a primary therapeutic target for Alzheimer’s disease (AD). However, just eliminating Aβ in patients with AD
Alzheimer’s disease drug development pipeline: 2024
New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer’s
Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications
Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM) are two prevalent conditions that present considerable public health issue in
More and more manipulated results in Alzheimer and Parkinson’s research
„Short road to discovery, winding road to use” Josef Pitha I assume that many of you remember the “story”
Patent application: gamma-cyclodextrin-based polymer for prevention or treatment of cholesterol metabolism-related diseases
RENATUS, a South Korea-based pharma company pioneering next generation cyclodextrin-based therapies for the safe treatment of cholesterol-associated diseases recently filed
Nature.com: HPBCD treatment improves learning and executive function in Alzheimer model mice
Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of